Caricamento azienda
Keep exploring
The themes Novo Nordisk A/S is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,36T USDA+
JNJJohnson & Johnson688,6B USDA+
MRKMerck & Co., Inc.364,3B USDA
NVSNovartis AG306,3B USDA
AMGNAmgen Inc.251,9B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 ott 2026CAGraded C, now A
Come guadagna
- Sales of prescription medicines for diabetes, obesity and other conditions
Compete con
Che cosa vende3
Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.
Chi lo compra3
- People with diabetes or obesity who obtain medicines through a prescription or buy them directly in self-pay channels.
- Pharmacies and telehealth providers that supply medicines to patients.
- Private insurers and public programs that cover prescription medicines, including Medicare Part D in the United States.
Su cosa si regge e cosa potrebbe romperlo
Da che cosa dipende l'attività
- 1Recent sales growth and product launches rely on glucagon-like peptide-1 (GLP-1) medicines, including semaglutide brands such as Wegovy and Ozempic.
- 2Access to obesity medicines in the United States depends on insurance coverage and what patients can afford to pay themselves; the company said most Wegovy pill prescriptions there were self-pay in Q2 2026.
- 3Commercial supply depends on manufacturing capacity; the company said its new active pharmaceutical ingredient facilities were contributing very little commercial supply in Q2 2026.
Che cosa potrebbe andare storto
- 1Competition and lower realized prices can reduce sales from obesity and diabetes medicines; the company cited intensifying United States competition and pricing pressure in Q2 2026.
- 2Generic versions of semaglutide can reduce sales where patent protection expires; the company reported early generic entries in some international markets.
- 3Cybersecurity breaches could disrupt the business.
Informazioni su Novo Nordisk A/S
Novo Nordisk makes medicines for diabetes and obesity, including Wegovy for weight management and Ozempic for type 2 diabetes. Its medicines reach patients through healthcare providers and pharmacies, with payment coming from insurers and public health programs or directly from patients. It also develops medicines for other conditions, including rare diseases.
- Sede
- Bagsværd, Denmark
- Fondata nel
- 1923
- Dipendenti
- around 66,700 (Q2 2026, medium)
- Quotata su
- New York Stock Exchange
- Chiusura dell'esercizio
- December 31
Costruito dai documenti depositati da Novo Nordisk A/S presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questa azienda rendiconta in DKK. Le cifre sono convertite in dollari a 1,00 USD = 6,7640 DKK, il tasso attuale, applicato allo stesso modo a tutti i periodi: così crescita e margini sono dell’azienda e non del cambio. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
